Trying to Get a GLP-1 Covered: What Actually Decides It

Nobody denies you for the reason you expect

A weight-loss prescription and insurance coverage are different decisions. I would start with the plan document rather than assume that meeting a clinical threshold guarantees payment. The drug name, covered indication, exclusions and authorization requirements can all affect the answer.

That distinction is useful before making phone calls. I would want the insurer’s actual criteria in front of me, so my questions address the coverage rule rather than a guessed reason for a denial.

The word that decides it

Insurers do not cover a molecule. They cover an indication — an approved use.

That is why the same tirzepatide can be covered under one brand name for type 2 diabetes and refused under another for weight management. Nothing about the chemical changed. The line in the formulary did.

So before anything else, the useful question for your prescriber is which label they are writing, and the useful question for your plan is what it does with that specific word.

What prior authorization actually is

Prior authorization is a request your clinician’s office sends asking the plan to approve coverage under its criteria. I would ask whether the request has been submitted, whether anything is missing, and when the plan expects a decision. Processing time varies. A denial should come with a reason and information about any available review or appeal; it is not a judgment about someone’s effort or worth.

What tends to be asked for: your BMI, any weight-related conditions, and often documentation that you tried something else first. That last one is called step therapy, and it is the part that surprises people — a plan can require a cheaper attempt before it will consider this one.

If it is denied, there is an appeal, and appeals are won more often than people expect because the first pass is frequently a paperwork mismatch rather than a real clinical objection. Ask the office to tell you the specific reason code. You cannot argue with "denied."

If you are on Medicare, there is a live program with an end date

This one is genuinely new and genuinely temporary, and both halves matter.

Medicare is running a GLP-1 Bridge: Wegovy and Zepbound for a $50 per month copay for eligible beneficiaries, running 1 July 2026 through 31 December 2027¹. Lilly says its Foundayo pill is covered under the Bridge at the same $50².

Two things to hold alongside that. First, eligibility runs through your provider attesting you meet clinical criteria — nobody here can tell you whether you qualify. Second, and this is the part that will catch people: the $50 does not count toward your Part D deductible or your annual out-of-pocket maximum. It sits outside the benefit, so it does not move you toward the cap the way your other drug spending does.

There is also a broader five-year BALANCE model behind it — but its Medicare Part D component was announced as indefinitely delayed in April 2026, so it is not something to plan around yet.

If you are on Medicaid, it depends on your state, and the map is shrinking

Coverage of GLP-1s for obesity is optional for states, and as of January 2026 only 13 state Medicaid programs covered them under fee-for-service — down from 16 the year before¹.

That decline is the part I would not have guessed, and I had assumed the map only ever grew. It is worth checking your own state rather than assuming last year's answer still holds. I keep every state in one table here: GLP-1 coverage by state.

What I would actually do, in order

1. 1.Ask your prescriber which indication they are writing for.
2. 2.Ask your plan — by phone, and write down who you spoke to — whether that indication is covered, and whether step therapy applies.
3. 3.If denied, get the reason code and appeal it. Do not restart the whole process somewhere else first.
4. 4.Only then price the cash route, at the dose you will end up on rather than the starting one.

Keeping the next step specific

I would keep a small record of the plan’s criteria, the authorization status, the quoted pharmacy cost and the next action. That gives each call a purpose. No one can promise approval from a general article; the useful result is knowing exactly what my plan requires and which questions remain unanswered.

None of this is medical, legal or insurance advice, and coverage rules change faster than any article can.

If coverage is unavailable, I would compare the cash offer’s medication, required membership and renewal terms together. The reviews of Collective, Nova, Believe Health and Solaya MD explain the different ways providers disclose those costs. An advertised starting figure is not enough to establish what my ongoing treatment would cost.

The opposite approach exists too, and it is easier to budget against: AHBARx, Nex Gen Rx and Goldspan Health all price cash-pay up front, though Goldspan makes you click out to another storefront to see it, and Oria Meds advertises figures on its front page that do not appear on the plan menu.

The MEDGm review discusses branded and compounded options and how its fees are presented. I would ask for the exact brand, any membership charge, the pharmacy price and the ongoing total in writing. A membership quote alone does not tell me what the medicine will cost.